Total buying$00 buys
TNGX
Tango Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$859k5 sells
Net open-market−$859kBuying minus selling
Active insiders2Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 05, 2026
Open-market transaction mix · 5 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 3 | 0 | $0 | $198k | -$198k |
| Oct 2026 | 0 | 2 | 0 | $0 | $660k | -$660k |
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (1)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- CA-$520.4k
- NJ-$198.6k
TNGX transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
TNGXTango Therapeutics, Inc. | Crystal AdamPRES · R · D | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
TNGXTango Therapeutics, Inc. | Crystal AdamPRES · R · D | S · sale10b5-1 detectedSEC filing ↗ | -$15.1kView disclosure → | |
TNGXTango Therapeutics, Inc. | Crystal AdamPRES · R · D | S · sale10b5-1 detectedSEC filing ↗ | -$645kView disclosure → | |
TNGXTango Therapeutics, Inc. | Crystal AdamPRES · R · D | M · exercise10b5-1 detectedSEC filing ↗ | $140kView disclosure → | |
TNGXTango Therapeutics, Inc. | Newcomb JessicaPAO | S · sale10b5-1 detectedSEC filing ↗ | -$60.4kView disclosure → | |
TNGXTango Therapeutics, Inc. | Newcomb JessicaPAO | S · sale10b5-1 detectedSEC filing ↗ | -$122kView disclosure → | |
TNGXTango Therapeutics, Inc. | Newcomb JessicaPAO | S · sale10b5-1 detectedSEC filing ↗ | -$15.9kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period7transactionstxns
- S · Open-market sells · dominant5 · 71%
- M · Option exercise2 · 29%
Activity by reported role
A joint filing can contribute to multiple rolesD4
PRES4
R4
PAO3
Reported Holdings After
Separated by insider, security, and ownership type
Newcomb JessicaCommon Stock · Direct
59,121Sep 22, 2026
Crystal AdamCommon Stock · Direct
115,743Oct 01, 2026
Crystal AdamStock Option (Right to Buy) · Direct
233,040Oct 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
Tango Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Tango Therapeutics, Inc.?
Crystal Adam, Newcomb Jessica.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Crystal Adam reported a sale on Oct 01, 2026 valued at $15.1k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $859,408.76. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.